Preparation of stabilized submicron fenofibrate crystals on niacin as a hydrophilic hydrotropic carrier

References

• Adkins JC, Faulds D. 1997. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 54(4):615–633.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Pancholi SS, Jain NK, Agrawal GP. 2004. Hydrotropic solubilization of nimesulide for parenteral administration. Int J Pharm. 274(1-2):149–155.
   PubMedGoogle Scholar
• Ammar H, Khalil R. 1996. Effect of aromatic hydrotropes on the solubility of oxamniquine. Part 2: Effect of nicotinamide and sodium salts of benzoic, naphthoic, nicotinic and isonicotinic acids. Pharmazie. 51:490–493.
   Web of Science ®Google Scholar
• Arafa MF, El-Gizawy SA, Osman MA, El Maghraby GM. 2018. Xylitol as a potential co-crystal co-former for enhancing dissolution rate of felodipine: preparation and evaluation of sublingual tablets. Pharm Dev Technol. 23(5):454–463.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, Taylor AA, Giordano TP, Sekhar RV, Clark P, et al. 2011. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab. 96(7):2236–2247.
   PubMed Web of Science ®Google Scholar
• Blane GF. 1989. Review of European clinical experience with fenofibrate. Cardiology. 76(suppl. 1):1–13.
   PubMedGoogle Scholar
• Bouledjouidja A, Masmoudi Y, Speybroeck MV, Schueller L, Badens E. 2016. Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide. Int J Pharm. 499(1–2):1–9.
   PubMedGoogle Scholar
• Bruckert E, Labreuche J, Amarenco P. 2010. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 210(2):353–361.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, et al. 2016. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, et al. 2011. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Cho YD, Park YJ. 2014. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate. Arch Pharm Res. 37(2):193–203.
   PubMed Web of Science ®Google Scholar
• Das S, Paul S. 2017. Hydrotropic solubilization of sparingly soluble riboflavin drug molecule in aqueous nicotinamide solution. J Phys Chem B. 121(37):8774–8785.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R. 2006. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 29(6):268–273.
   PubMed Web of Science ®Google Scholar
• Di YY, Hong YP, Kong YX, Yang WW, Tan ZC. 2009. Synthesis, characterization, and thermochemistry of the solid state coordination compound Zn(Nic)2·H2O(s) (Nic = nicotinic acid). J Chem Thermodyn. 41(1):80–83.
   Web of Science ®Google Scholar
• Elbagerma MA, Edwards HGM, Munshi T, Hargreaves MD, Matousek P, Scowen IJ. 2010. Characterization of new cocrystals by Raman spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and transmission Raman spectroscopy. Cryst Growth Des. 10(5):2360–2371.
   Web of Science ®Google Scholar
• El-Gizawy SA, Osman MA, Arafa MF, El Maghraby GM. 2015. Aerosil as a novel co-crystal co-former for improving the dissolution rate of hydrochlorothiazide. Int J Pharm. 478(2):773–778.
   PubMedGoogle Scholar
• Geng H, Zhao Y, Liu J, Cui Y, Wang Y, Zhao Q, Wang S. 2016. Hollow mesoporous silica as a high drug loading carrier for regulation insoluble drug release. Int J Pharm. 510(1):184–194.
   PubMedGoogle Scholar
• Guichard JP, Blouquin P, Qing Y. 2000. A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin. 16(2):134–138.
   PubMed Web of Science ®Google Scholar
• Guichard JP, Sauron RL. 1993. A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr Ther Res. 54(5):610–614.
   Web of Science ®Google Scholar
• Guivarc’h PH, Vachon MG, Fordyce D. 2004. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther. 26(9):1456–1469.
   PubMed Web of Science ®Google Scholar
• Ige PP, Baria RK, Gattani SG. 2013. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B Biointerfaces. 108:366–373.
   PubMed Web of Science ®Google Scholar
• Ito MK. 2015. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature. Atherosclerosis. 242(2):647–656.
   PubMed Web of Science ®Google Scholar
• Kalivoda A, Fischbach M, Kleinebudde P. 2012. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. Int J Pharm. 429(1-2):58–68.
   PubMedGoogle Scholar
• Kawakami K, Zhang S, Chauhan RS, Ishizuka N, Yamamoto M, Masaoka Y, Kataoka M, Yamashita S, Sakuma S. 2013. Preparation of fenofibrate solid dispersion using electrospray deposition and improvement in oral absorption by instantaneous post-heating of the formulation. Int J Pharm. 450(1-2):123–128.
   PubMedGoogle Scholar
• Khan KA. 1975. The concept of dissolution efficiency. J Pharm Pharmacol. 27(1):48–49.
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim S, Papp M, Park K, Pinal R. 2010. Hydrotropic solubilization of poorly water-soluble drugs. J Pharm Sci. 99(9):3953–3965.
   PubMed Web of Science ®Google Scholar
• Ling H, Luoma JT, Hilleman D. 2013. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiol Res. 4(2):47–55.
   PubMedGoogle Scholar
• Madan JR, Kamate VJ, Awasthi R, Dua K. 2017. Formulation, characterization and in-vitro evaluation of fast dissolving tablets containing gliclazide hydrotropic solid dispersions. Recent Pat Drug Deliv Formul. 11(2):147–154.
   PubMedGoogle Scholar
• Maravajhala V, Dasari N, Sepuri A, Joginapalli S. 2009. Design and evaluation of niacin microspheres. Indian J Pharm Sci. 71(6):663–669.
   PubMed Web of Science ®Google Scholar
• Mishra AK, Vachon MG, Guivarc’h PH, Snow RA, Pace GW. 2002. IDD technology: oral delivery of water-insoluble drugs using phospholipid-stabilized microparticulate IDD formulations. In: Rathbone MJ, Hdgraft J, Roberts MS, editors. Modified-release drug delivery technology. New York (NY): Marcel Dekker, Inc; p. 151–175.
   Google Scholar
• Patel SK, Lavasanifar A, Choi P. 2010. Molecular dynamics study of the encapsulation capability of a PCl-PEO based block copolymer for hydrophobic drugs with different spatial distributions of hydrogen bond donors and acceptors. Biomaterials. 31(7):1780–1786.
   PubMed Web of Science ®Google Scholar
• Quan G, Wu Q, Zhang X, Zhan Z, Zhou C, Chen B, Zhang Z, Li G, Pan X, Wu C. 2016. Enhancing in vitro dissolution and in vivo bioavailability of fenofibrate by solid self-emulsifying matrix combined with SBA-15 mesoporous silica. Colloids Surf B Biointerfaces. 141:476–482.
   PubMed Web of Science ®Google Scholar
• Rehman M, Shekunov BY, York P, Colthorpe P. 2001. Solubility and precipitation of nicotinic acid in supercritical carbon dioxide. J Pharm Sci. 90(10):1570–1582.
   PubMed Web of Science ®Google Scholar
• Saleh AM, El-Khordagui LK. 1985. Hydrotropic agents: a new definition. Int J Pharm. 24(2–3):231–238.
   Google Scholar
• Sanghvi R, Evans D, Yalkowsky SH. 2007. Stacking complexation by nicotinamide: a useful way of enhancing drug solubility. Int J Pharm. 336(1):35–41.
   PubMedGoogle Scholar
• Shi NQ, Zhang Y, Li Y, Lai HW, Xiao X, Feng B, Qi XR. 2017. Self-micellizing solid dispersions enhance the properties and therapeutic potential of fenofibrate: advantages, profiles and mechanisms. Int J Pharm. 528(1–2):563–577.
   PubMedGoogle Scholar
• Shipman KE, Strange RC, Ramachandran S. 2016. Use of fibrates in the metabolic syndrome: a review. WJD. 7(5):74–88.
   Google Scholar
• Trivedi MK, Branton A, Trivedi D, Nayak G, Bairwa K, Jana S. 2015. Spectroscopic characterization of disulfiram and nicotinic acid after biofield treatment. J Anal Bioanal Tech. 6(5):1000265.
   Google Scholar
• Uejo F, Limwikrant W, Moribe K, Yamamoto K. 2013. Dissolution improvement of fenofibrate by melting inclusion in mesoporous silica. Asian J Pharm Sci. 8(6):329–335.
   Google Scholar
• Vogt M, Kunath K, Dressman JB. 2008. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm. 68(2):283–288.
   PubMed Web of Science ®Google Scholar
• Vora P, Menon D, Samtani M, Dollimore D, Alexander K. 2001. A preformulation study of nicotinic acid with an emphasis on the effect of compaction and grinding on its thermal behavior. Instrum Sci Technol. 29(3):231–245.
   Web of Science ®Google Scholar
• Wang SX, Tan ZC, Di YY, Xu F, Wang MH, Sun LX, Zhang T. 2004. Calorimetric study and thermal analysis of crystalline nicotinic acid. J Therm Anal Calorim. 76(1):335–342.
   Web of Science ®Google Scholar
• Weissig V, Pettinger TK, Murdock N. 2014. Nanopharmaceuticals (part 1): products on the market. Int J Nanomed. 9:4357–4373.
   PubMed Web of Science ®Google Scholar
• Yin SX, Franchini M, Chen J, Hsieh A, Jen S, Lee T, Hussain M, Smith R. 2005. Bioavailability enhancement of a COX-2 inhibitor, BMS-347070, from a nanocrystalline dispersion prepared by spray-drying. J Pharm Sci. 94(7):1598–1607.
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Kim DW, Oh YK, Yong CS, Kim JO, Choi HG. 2015. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation. Int J Nanomed. 10:1819–1830.
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Mustapha O, Kim DW, Kim DS, Kim KS, Jin SG, Yong CS, Youn YS, Oh YK, Kim JO, Choi HG. 2016. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. Int J Nanomed. 11:213–221.
   PubMed Web of Science ®Google Scholar
• Zuo B, Sun Y, Li H, Liu X, Zhai Y, Sun J, He Z. 2013. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals. Int J Pharm. 455(1-2):267–275.
   PubMedGoogle Scholar